Lille

• First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of s … Pending
  2025-523593-16-00 5 Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III wel
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease Pending
  2025-523871-44-00 5 Cutaneous Manifestations of Lupus Erythematosus With or Without System
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer. Pending
  2025-523984-39-00 4 Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ … Pending
  2025-524095-27-00 4 HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ
• TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending
  2025-524213-84-00 5 Patients with advanced or metastatic ER+ HER2- breast cancer
• Real-world study to evaluate how effective and safe Pegcetacoplan is in patients with rare kidney diseases called C3G or IC-MPGN in multiple … Pending
  2025-524487-37-00 6 Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MP
• Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer Pending
  2025-524690-16-00 1 Solid Tumors
• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-523815-12-00 5 2026-07-06 Relapsed or Refractory Multiple Myeloma
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A Recruiting
  2025-522434-32-00 5 2026-07-01 Hemophilia A Without Inhibitors
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A Recruiting
  2025-522435-33-00 5 2026-06-17 Hemophilia A
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting
  2025-523576-23-00 5 2026-06-12 Unresectable Stage III non-small cell lung cancer without progression
• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Recruiting
  2025-524056-63-00 1 2026-06-05 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• Postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stent FRENCH24 ANIS Recruiting
  2024-515181-14-00 5 2026-05-20 Patients with preoperative biliary stent treated by pancreaticoduodene
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 5 2026-04-23 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Phase 1 trial of valemetostat and darolutamide in mCRPC Recruiting
  2025-522512-16-00 3 2026-04-23 Metastatic Castration Resistant Prostate Cancer (mCRPC)
• MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors … Recruiting
  2023-507485-10-00 9 2026-04-21 advanced breast cancer
• A Long-term Study of Navenibart in Participants with Hereditary Angioedema Recruiting
  2025-521142-22-00 5 2026-03-27 Hereditary Angioedema
• A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Recruiting
  2024-516476-15-00 9 2026-03-04 Advanced gastrointestinal stromal tumor (GIST)
• First-in-Human trial of DS9051b in participants with advanced solid tumors Recruiting
  2025-521886-28-00 1 2026-02-19 Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Cast

Showing 49–72 of 703 trials